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Research
Inorganic arsenic (iAs) is a recognized carcino-
gen and toxicant [National Research Council 
(NRC) 2001; World Health Organization 
(WHO) International Programme on 
Chemical Safety 2001] that is commonly 
present in groundwater. Causal relationships 
between long-term elevated iAs exposure and 
cancer of the skin, lung, and bladder have been 
accepted [International Agency for Research 
on Cancer (IARC) 2004, 2009]. Although cer-
tain populations, such as in Bangladesh, West 
Bengal, Taiwan, parts of China, Argentina, 
and northern Chile, have been exposed to 
very high concentrations of iAs in drinking 
water (several hundred micrograms per liter) 
(IARC 2004), there is widespread exposure 
worldwide to low concentrations of iAs, in 
the range of 5–50 μg/L in drinking water and 
5–100 μg/kg in food, especially cereals and veg-
etables (European Food Safety Authority 2009; 
Norton et al. 2010). The NRC risk assessment 
(NRC 2001) indicates a comparatively high 
cancer risk even at concentrations as low as 
10 μg/L in drinking water; however, these risk 
estimates, as well as current WHO, European 
Union, and U.S. drinking water guidelines 
(European Council 1998; U.S. Environmental 
Protection Agency 2001; WHO 2011), are 
based on linear extrapolation of cancer risks 
at low doses in studies with relatively high iAs 
exposure, mainly in Taiwan (Chen et al. 1985, 
1992; Chiou et al. 2001; Tseng et al. 1968; 
Wu et al. 1989). Concerns have been raised 
about the validity of such extrapolation, in part 
because accepted modes of action, which do 
not include direct DNA mutations, would be 
expected to result in a threshold dose response 
(Snow et al. 2005).
The effects of elevated iAs exposure on 
the risk of nonmelanoma skin cancer, mainly 
squamous cell carcinoma and basal cell carci-
noma (BCC), have been recognized in highly 
exposed populations for some time (Cabrera 
and Gomez 2003; Chen and Wang 1990; 
Chen et al. 1985, 2003; Guha Mazumder 
et al. 1998; Guo et al. 1998; Hsueh et al. 
1995; Knobeloch et al. 2006; Tsai et al. 1999; 
Tseng 1977; Tseng et al. 1968). However, 
there is little direct evidence of skin cancer 
risk resulting from exposure to drinking water 
containing < 100 μg/L iAs (Baastrup et al. 
2008; Karagas et al. 2001).
The Arsenic Health Risk Assessment and 
Molecular Epidemiology (ASHRAM) study 
aimed to quantify the risks of several can-
cer types in relation to long-term low-level 
iAs exposure via drinking water in Hungary, 
Romania, and Slovakia. The associations with 
BCC of the skin are presented here.
Materials and Methods
For the ASHRAM study, the study areas 
included districts in central Slovakia where 
drinking water is derived from a cracked hard 
rock aquifer, as well as districts in eastern 
Hungary and western Romania located on 
the Great Hungarian Plain, an alluvial basin 
that straddles the Hungarian–Romanian 
border. More precisely, the study included 
the Hungarian counties Bács-Kiskun, Békés, 
Csongrád, and Jász-Nagykun-Szolnok; the 
Romanian counties Arad and Bihor; and the 
Slovakian districts Nitra, Nove Zamky, and 
Levice within Nitra County, and Banska 
Bystrica, Brezno, Ziar nad Hronom, and 
Zarnovica within Banska Bystrica County 
(total population ~ 4.5 million). Routine 
monitoring of sources indicated that approx-
imately 1,100,000 individuals had used 
water with > 10 μg iAs/L, but generally 
< 100 μg/L, at some point during the past 
30 years (Hough et al. 2010). The study was 
conducted with individuals who provided 
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Ba c k g r o u n d: Inorganic arsenic (iAs) is a potent carcinogen, but there is a lack of information 
about cancer risk for concentrations < 100 μg/L in drinking water.
oBjectives: We aimed to quantify skin cancer relative risks in relation to iAs exposure < 100 μg/L 
and the modifying effects of iAs metabolism.
Me t h o d s : The Arsenic Health Risk Assessment and Molecular Epidemiology (ASHRAM) study, 
a case–control study, was conducted in areas of Hungary, Romania, and Slovakia with reported 
presence of iAs in groundwater. Consecutively diagnosed cases of basal cell carcinoma (BCC) of the 
skin were histologically confirmed; controls were general surgery, orthopedic, and trauma patients 
who were frequency matched to cases by age, sex, and area of residence. Exposure indices were con‑
structed based on information on iAs intake over the lifetime of participants. iAs metabolism status 
was classified based on urinary concentrations of methylarsonic acid (MA) and dimethylarsinic acid 
(DMA). Associations were estimated by multivariable logistic regression.
re s u l t s: A total of 529 cases with BCC and 540 controls were recruited for the study. BCC was 
positively associated with three indices of iAs exposure: peak daily iAs dose rate, cumulative iAs dose, 
and lifetime average water iAs concentration. The adjusted odds ratio per 10‑μg/L increase in average 
lifetime water iAs concentration was 1.18 (95% confidence interval: 1.08, 1.28). The estimated effect 
of iAs on cancer was stronger in participants with urinary markers indicating incomplete metabolism 
of iAs: higher percentage of MA in urine or a lower percentage of DMA.
co n c l u s i o n: We found a positive association between BCC and exposure to iAs through drinking 
water with concentrations < 100 μg/L.
key w o r d s : low‑dose arsenic, metabolism, methylation, skin neoplasms, urine. Environ Health 
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written informed consent and were part of the 
majority Caucasian population, excluding the 
minority Roma population. Ethical approval 
was obtained from the Ethical Committee 
of the National Health Research Council 
and the Regional Ethical Committee of the 
Szentgyörgyi Albert University of Szeged 
(Hungary), from local hospitals and public 
health departments (Romania), and from eth-
ical committees established in hospitals and 
state health institutes (Slovakia) included in 
the study.
In the absence of population registers, we 
worked with public health agencies to iden-
tify incident cases of BCC [International 
Classification of Diseases, 10th Revision 
(ICD-10) code C44 (WHO 1993)] and con-
trols diagnosed among those 30–79 years of 
age in the same areas. Recruitment of cases 
and controls was carried out over 21 months 
(January 2003–September 2004). Because 
BCC cases may be diagnosed in primary or 
private care, a case–control study of BCC based 
on cases identified only at hospitals may pro-
vide an incomplete ascertainment. However, 
we determined that pathologists at public hos-
pitals were responsible for histological con-
firmation of all BCC cases in the study areas. 
Therefore, identification of BCC cases entailed 
a system whereby each pathologist would 
inform the local study coordinator every time 
a new case of BCC was diagnosed by histol-
ogy, so that the identification of BCC cases did 
not require cooperation by the large network 
of hospital- and community-based clinicians 
responsible for diagnosing cases.
Hospital-based case–control studies have 
been criticized because of the potential for selec-
tion bias resulting from recruitment of controls 
from a population systematically different from 
the source population for cases. In addition, 
selection bias would result if recruitment of 
cases and controls differed by geographical area 
that may be associated with degree of potential 
iAs exposure. Therefore, to ensure equivalent 
geographic coverage of populations for sampling 
both cases and controls, we recruited controls 
from all 24 hospitals in the study area, includ-
ing six smaller hospitals in more peripheral 
areas that did not have pathology departments 
involved in the histological confirmation of 
BCC cases. All of the targeted hospitals agreed 
to participate in the study. Controls were gen-
eral surgery in-patients (appendicitis, abdomi-
nal hernia, duodenal ulcer, or cholelithiasis, 
with ICD-10 diagnostic codes K35–K37,   
K40–K46, K26, K80) and orthopedic and 
trauma patients (fractures, with ICD-10 diag-
nostic codes SO2, S12, S22, S32, S42, S52, 
S62, S72, S82, S92, TO2, TO8, T10, T12) 
30–79 years of age. We recruited controls diag-
nosed with a variety of conditions from two 
distinct hospital departments to reduce the 
possibility that geographic variation in patterns 
of diagnosis and clinical practice might lead to 
systematic differences between control and base 
population   distributions.
Controls served as the comparison group 
for analyses of other cancers (bladder and kid-
ney) in addition to BCC. Therefore, controls 
were frequency matched to all potential cancer 
cases by sex, 5-year age band, and residence in 
the same county/region of the study area. Cases 
and controls were included if they had resided 
in the study area for at least 1 year during their 
lifetime. Because a complete roster of all eligi-
ble controls admitted to all the hospitals in the 
region was not available, recruitment of con-
trols was proportional to the expected number 
of potential controls at each hospital indicated 
by past data. Control selection continued until 
the target number of interviews was completed. 
This procedure led to a systematic rotation 
between hospitals and control diagnoses and 
therefore constructed a series of controls that 
was similar to that of the cases for age group, 
sex, and county of residence while minimizing 
the opportunity for systematic error in control 
selection (Leonardi et al. 2004). Clinicians and 
pathologists were blind to the exposure status 
of cases and controls.
A face-to-face interview was conducted 
with each participant to obtain a detailed 
residential history focused on identification 
of drinking water sources at home and infor-
mation on potential confounders, including 
sunlight exposure, skin characteristics, educa-
tional attainment, sex, age, smoking history, 
height, and weight reported for age 20, before 
their illnesses. Participants also completed 
interviewer-administered food frequency ques-
tionnaires (Hough et al. 2010). Interviewers 
from the three countries were staff of public 
health institutes who had attended training 
workshops to ensure consistent approach to 
data collection following the study protocol. 
Interviewers asked participants about the hours 
per day spent in the sun at different ages over 
their lifetime, as well as self-reported skin com-
plexion, eye color, skin reaction to midday sun, 
and history of sunburns and red skin from sun 
exposure. From the questionnaire responses, 
four indices of exposure to sunlight were gen-
erated: peak exposure was defined as the high-
est annual number of hours of exposure to the 
sun; cumulative lifetime exposure, as the life-
time number of hours of exposure to the sun; 
skin sensitivity to burns, as an index based on 
the intensity of the cutaneous reaction to 1-hr 
midday sun exposure of the upper trunk; and 
skin complexion, as the self-reported complex-
ion of the skin as light, medium, or dark.
Exposure model. For each individual, 
the concentrations of iAs in drinking water 
at addresses over their lifetime were derived 
from measurements at the time of the study 
and historical data provided by national water 
authorities as described in detail elsewhere 
(Hough et al. 2010). When historical data 
were unavailable, past concentrations of iAs 
in village and private wells were assumed to be 
the same as currently measured concentrations 
in water samples from the same wells. Address 
and water source data were collected on up to 
nine different residences over each person’s 
lifetime, and, at minimum, we attempted to 
measure iAs in current samples obtained from 
the first, last, and longest reported addresses. 
All water samples were analyzed by the same 
laboratory in Cluj-Napoca, Romania, using 
hydride generation/atomic absorption spec-
trometry accompanied by strict quality assur-
ance and quality control (QA/QC) procedures. 
Based on sample measurements and historical 
information, concentrations of iAs in residen-
tial supplies were assigned for 80.09% of case 
and 80.07% of control lifetime years. Based 
on these lifetime concentration profiles and 
individual fluid intakes, three exposure indi-
ces were constructed: the peak daily dose rate 
(micrograms iAs per day) at the participant’s 
residence with the highest water iAs concentra-
tion, the time-weighted average concentration 
(micrograms iAs per liter) over the lifetime of 
each individual, and the lifetime cumulative 
dose (grams iAs) (Hough et al. 2010).
Each participant was asked to provide an 
early morning urine sample. The samples were 
placed in a freezer at –20°C within 15 min of 
collection to limit influence on the chemical 
species of iAs in urine. Urinary metabolites of 
iAs, methylarsonic acid [MA, MA(V) unless 
otherwise noted] and dimethylarsinic acid 
[DMA, DMA(V) unless otherwise noted] were 
measured with high-performance liquid chro-
matography with inductively coupled plasma/
mass spectrometry (Lindberg et al. 2006). Total 
urinary metabolites were computed as the sum 
of iAs, MA, and DMA. Concentrations of iAs 
in urine were adjusted to the average specific 
gravity in the population. Details on concen-
trations of iAs in water and urine samples and 
their relevance for exposure assessment are 
available elsewhere (Lindberg et al. 2006).
Statistical analyses. Data were analyzed in 
STATA (version 10; StataCorp 2007) using 
separate multivariable logistic regression models 
for each iAs exposure index that included vari-
ables representing potential confounders defined 
a priori: several indices of sun exposure, age, 
sex, number of years of education (proxy for 
socioeconomic status), and county. Preliminary 
analyses identified skin response to 1-hr mid-
day sun and skin complexion as the sunlight 
exposure indices most strongly predicting BCC 
risk in this population, so these were included 
in models including exposure. This population 
was part of a larger study of skin, bladder, and 
kidney cancers with a common referent popu-
lation, and the targets were for similar num-
bers of controls and all cancers per county. The 
relative numbers of the different cancers varied Arsenic and cancer: Hungary, Romania, and Slovakia
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geographically, so the BCC case:control ratio 
varied arbitrarily by county (and country). This 
geographic matching was accounted for in anal-
yses by using logistic regression conditional on 
county (STATA command xtlogit, fe), which 
also controlled for variation across counties 
(clustering) of unmeasured risk factors.
Quintiles of exposure for the controls were 
defined for each exposure index and used for 
classifying cases and controls to explore the 
shape of the relationships. The trend across 
quintile was assessed by fitting a linear term 
for exposure quintile. To evaluate possible 
departure from linearity, likelihood ratio tests 
were used to compare the fit of models with 
exposure quintile as a categorical variable 
  versus quintile as a linear term.
Each index was also treated as a continu-
ous variable in regression models to estimate 
the overall slope of the exposure response, 
with skin cancer relative risk expressed as odds 
ratios (ORs) for unit changes in each exposure: 
10-μg/L increase in lifetime average iAs con-
centration, 10-μg/day increase in peak iAs daily 
dose rate, and increase of 0.274 g in cumula-
tive iAs dose derived from 50 years of drinking 
1.5 L water per day containing 10 μg/L iAs.
We conducted analyses adjusted for smok-
ing and body mass index (BMI), but including 
these covariates did not alter the magnitude 
of associations very much. Because neither 
smoking nor BMI is a likely confounder in a 
study of BCC, we did not include them in the 
reported analyses.
Because other iAs exposure routes, par-
ticularly diet, may be significant when con-
centrations of iAs in drinking water are low 
(Lindberg et al. 2006), we performed analy  ses 
that excluded those with a sum of iAs metabo-
lites in urine < 2.5 μg/L (in line with Lindberg 
et al. 2006). Because of potential interest 
in exposure to < 50 μg/L of iAs in drinking 
water, a further sensitivity analysis was carried 
out after excluding participants with lifetime 
average iAs concentrations above the 90th per-
centile of lifetime average iAs concentrations 
(40.7 μg/L), within the group with a sum of 
iAs metabolites ≥ 2.5 μg/L.
The principal metabolic data were a priori 
defined as the percentage of MA and DMA (in 
relation to total concentration of iAs metabo-
lites) in the urine (MA% and DMA%, respec-
tively). Stratified analyses were conducted to 
evaluate effect modification by methylation 
efficiency on the association between BCC 
and iAs exposure. Two dichotomous variables 
representing DMA% and MA% below and 
above the median were modeled along with 
multiplicative interaction terms between each 
dichotomous variable and the iAs exposure 
indices (as continuous variables). Modification 
of the association between iAs and BCC by 
DMA and MA was evaluated based on Wald 
tests (Clayton and Hills 1993).
Results
Of the 1,406 patients invited, 1,197 (85.1%) 
consented to participate in the study (81.6% 
among cases, 90.0% among controls). Later, 
96 potential cases were excluded because they 
had skin cancer other than BCC, 34 because 
they did not have histological confirmation, 
and 4 for other reasons. Thus, in total, the 
study included 1,069 valid participants, of 
whom 529 were BCC cases and 540 were con-
trols. Consistent with expectations for BCC, a 
cancer known to be caused by sun exposure, 
cases had a higher prevalence of skin burns in 
response to sun exposure than did controls, 
as well as a higher prevalence of light skin 
  complexion (Table 1).
The lifetime average iAs concentration in 
residential drinking water had a median value 
of 1.2 μg/L, with an interquartile range (IQR) 
of 0.7–13.8 μg/L. It is evident from the distri-
bution of lifetime average iAs concentration 
(quintiles of controls) shown in Table 2 that 
much of the population (first three quintiles) 
had exposure < 7 μg/L.
Arsenic and risk of BCC. In general, ORs 
increased with increasing iAs exposure categories, 
and all trend tests for the linear relationship 
between the categorical exposure variable and 
BCC were statistically significant (Table 2). 
Comparison by likelihood ratio tests of models 
with quintile of exposure as a categorical vari-
able and a linear variable did not provide evi-
dence of nonlinearity in the exposure–response   
relationship. Subsequent analyses were con-
ducted based on the assumption that the dose–
response relation between iAs exposure indexes 
and BCC can be summarized appropriately 
using simple continuous exposure variables.
All three iAs exposure indices were sig-
nificantly associated with BCC when adjusted 
for county, age, and sex, and ORs were com-
parable after further adjustment for educa-
tion, skin response to 1-hr midday sun, and 
skin complexion (Table 2). Associations were 
also significant when exposures were mod-
eled as continuous variables, with similar 
effect estimates after excluding individuals 
whose sum of iAs metabolites in current urine 
was < 2.5 μg/L (Table 3). Associations were 
increased after further excluding participants 
with lifetime average iAs water concentration 
above the 90th percentile (41 μg/L).
Table 1. Study population and characteristics [n (%)].
Characteristic Cases Controls Total (n)
Country/county 
Hungary, total 160 (30.3) 249 (46.1) 409
Bács-Kiskun 90 (17.1) 101 (18.7) 191
Békés 23 (4.4) 23 (4.3) 46
Csongrád 24 (4.5) 61 (11.3) 85
Jász-Nagykun-Szolnok 23 (4.4) 64 (11.9) 87
Romania, total 158 (29.9) 156 (28.9) 314
Arad 90 (17.0) 100 (18.5) 190
Bihor 68 (12.9) 56 (10.4) 124
Slovakia, total 211 (39.9) 135 (25.0) 346
Banska Bystrica 92 (17.4) 70 (13.0) 162
Nitra 119 (22.5) 65 (12.0) 184
Age (years)
< 45 20 (3.9) 55 (10.3) 75
45–49 33 (6.4) 47 (8.8) 80
50–54 31 (6.0) 61 (11.4) 92
55–59 63 (12.1) 77 (14.5) 140
60–64 65 (12.5) 76 (14.3) 141
65–69 106 (20.4) 83 (15.6) 189
70–74 113 (21.7) 78 (14.7) 191
75–79 89 (17.1) 56 (10.5) 145
Missing 9 7 16
Sex
Male 237 (44.8) 278 (51.5) 515
Female 292 (55.2) 262 (48.5) 554
Skin response to 1-hr midday sun
Blistered 71 (13.7) 59 (11.1) 130
Sunburned 114 (22.0) 83 (15.6) 197
Mild burn 169 (32.6) 161 (30.3) 330
Tan 157 (30.3) 206 (38.8) 363
No change 7 (1.4) 22 (4.1) 29
Missing 11 9 20
Skin complexion
Light 271 (51.3) 222 (41.2) 493
Medium 241 (45.6) 258 (47.9) 499
Dark 16 (3.0) 59 (11.0) 75
Missing 1 1 2
Total 529 (100.0) 540 (100.0) 1,069
Years of education (mean ± SD) 10.1 ± 4.1 10.2 ± 3.7 10.1 ± 3.9Leonardi et al.
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Effect modification by iAs metabolism. 
Median DMA% was 76.6% (median con-
centration, 4.0 μg/L; IQR, 2.1–9.7 μg/L), 
and median MA% was 15.8% (median con-
centration, 0.8 μg/L IQR, 0.4–2.1 μg/L; 
Table 4). Among participants with sum of 
iAs metabolites ≥ 2.5 μg/L, associations with 
all three indices of iAs exposure were stron-
ger in participants with low DMA% or high 
MA%, with little or no evidence of associa-
tions among participants with high DMA% 
or low MA%. Similar results were obtained 
for the overall group (including those with 
metabolites < 2.5 μg/L; data not shown).
Discussion
The ASHRAM study demonstrates strong 
evidence of an association between long-term 
low-level exposure to iAs in drinking water 
and BCC. To our knowledge this is the first 
report of a significant association between 
BCC and average drinking water iAs con-
centrations < 50 μg/L—concentrations com-
mon in many countries and affecting many 
millions of people. In addition, individuals 
with less efficient iAs methylation to DMA 
appeared to be at higher risk of BCC in asso-
ciation with iAs exposure. The relative risk of 
BCC was elevated in relation to all three indi-
ces of long-term iAs exposure (lifetime average 
concentration, cumulative and peak dose), and 
the relationship remained significant after con-
trolling for potential confounders, including 
indices of ultraviolet exposure.
Hospital-based case–control studies with 
a specific disease outcome have as their sec-
ondary population base a cohort of people 
who theoretically would be admitted to that 
hospital had they contracted the outcome dis-
ease (Miettinen 1985; Wacholder et al. 1992a, 
1992b). Selection bias could arise from sys-
tematic differences in selection of cases and 
controls. Difference in unmeasured con-
founders between countries and counties was 
addressed in part by including county indica-
tor variables in all models. Geographic varia-
tion in case versus control ascertainment could 
potentially lead to biased estimates of iAs effect 
if associated with geographic variation in iAs 
exposure. To optimize case ascertainment, we 
collaborated with all pathologists qualified to 
make diagnoses of BCC in the study areas. 
To minimize the potential for selection bias 
associated with control selection, we included 
all health care facilities where control diagno-
ses were produced, whether or not BCC cases 
were diagnosed at the facility. In addition, we 
identified several potentially suitable control 
diagnoses, including both general surgery and 
trauma. Overall, we believe that we achieved 
similar countywide coverage for cases and con-
trols and minimized potential bias due to geo-
graphic differences in ascertainment related to 
iAs exposure.
A validation study was conducted to 
compare the proportion of controls from 
larger cities and towns with the proportion 
of base population from the same towns. 
Together, larger cities and towns constitute 
a more urban “subcounty area” than the 
smaller towns and villages that account for 
the remaining portions of the study counties. 
From census figures in the three countries 
(Hungarian Central Statistical Office 2011; 
National Institute of Statistics, Romania 
2011a, 2011b; Statistical Office of the Slovak 
Republic 2009), we identified base popula-
tion counts for geographic areas at subcounty 
level (3,503,581) and in the larger cities and 
Table 2. Results of logistic regression models of iAs exposure by quintile and BCC in the ASHRAM study 
population [OR (95% confidence interval)].
Arsenic exposure index/quintile  
(range of exposure in controls) Adjusteda
Additionally 
adjustedb
Trend test 
(p-value)
Lifetime average iAs concentration (μg/L) 0.001
0.00–0.68 1.00 1.00
0.68–0.98 1.27 (0.82, 1.97) 1.39 (0.89, 2.19)
0.98–7.00 1.02 (0.67, 1.56) 1.20 (0.77, 1.88)
7.10–19.43 1.63 (0.93, 2.85) 1.73 (0.97, 3.11)
19.54–167.29 2.81 (1.62, 4.87) 3.03 (1.70, 5.41)
Peak daily iAs dose rate (μg/day) 0.001
0.00–0.73 1.00 1.00
0.73–1.48 0.93 (0.62, 1.39) 0.91 (0.59, 1.39)
1.48–9.09 1.29 (0.86, 1.95) 1.55 (1.00, 2.41)
9.09–32.23 1.78 (1.05, 3.02) 1.76 (1.01, 3.07)
32.23–242.14 2.31 (1.32, 4.03) 2.50 (1.39, 4.49)
Cumulative iAs dose (g) 0.001
0.00–0.01 1.00 1.00
0.01–0.03 1.02 (0.68, 1.52) 1.09 (0.72, 1.67)
0.03–0.13 1.19 (0.78, 1.81) 1.46 (0.93, 2.27)
0.13–0.55 1.73 (1.02, 2.91) 1.76 (1.02, 3.04)
0.55–4.46 2.45 (1.39, 4.32) 2.63 (1.45, 4.78)
Relative risks of BCC were estimated as ORs comparing risk of cancer in a quantile with the quintile of lowest exposure. 
Range of iAs exposure within each quintile is expressed in the unit of measure specific for each exposure index.
aAdjusted for county, age, and sex, based on n = 1,022 for peak dose rate, n = 1,025 for lifetime average concentration, 
and n = 1,011 for cumulative dose. bAdditionally adjusted for education, skin response to 1-hr midday sun, and skin com-
plexion, based on n = 989 for peak dose rate, n = 992 for lifetime average concentration, n = 979 for cumulative dose.
Table 3. Logistic regression models of iAs exposure and BCC in the ASHRAM study population [OR (95% 
confidence interval)].
Arsenic exposure index
All observations 
(n = 1,069)
Observations 
with metabolites 
≥ 2.5 μg/L (n = 856)
Observations with metabolites 
≥ 2.5 μg/L and lifetime average 
As < 40.7 μg/L (n = 736)
Lifetime average As concentration 1.18 (1.08, 1.28) 1.15 (1.06, 1.26) 1.41 (1.14, 1.76)
Peak daily As dose rate 1.13 (1.07, 1.20) 1.12 (1.06, 1.19) 1.18 (1.04, 1.33)
Cumulative As dose 1.10 (1.01, 1.19) 1.08 (1.00, 1.18) 1.16 (0.95, 1.41)
Relative risks of BCC were estimated as ORs for unit changes in exposure: a 10-μg/L increase in lifetime average iAs 
concentration, a 10-μg/day increase in peak iAs daily dose rate, or an increase in cumulative iAs dose derived from 
50 years of drinking 1.5 L water/day containing 10 μg/L iAs. All models adjusted for county, age, sex, education, skin 
response to 1-hr midday sun, and skin complexion.
Table 4. Associations between BCC and As according to urine iAs metabolite levels among participants 
with sum of iAs metabolites ≥ 2.5 μg/L (n = 856).
Arsenic exposure index
< Mediana 
[ORb (95% CI)] 
≥ Mediana 
[ORb (95% CI)] p-Valuec
Lifetime average concentration
DMA% 1.21 (1.10, 1.35) 1.03 (0.92, 1.15) 0.017
MA% 1.04 (0.94, 1.17) 1.21 (1.09, 1.35) 0.032
Peak daily As dose rate
DMA% 1.14 (1.06, 1.23) 1.05 (0.96, 1.15) 0.098
MA% 1.05 (0.97, 1.15) 1.15 (1.06, 1.23) 0.095
Cumulative As dose
DMA% 1.11 (1.01, 1.22) 0.99 (0.88, 1.12) 0.119
MA% 1.02 (0.91, 1.14)  1.10 (1.00, 1.22) 0.222
Relative risks of BCC were estimated as ORs for unit changes in exposure: a 10 μg/L increase in lifetime average iAs 
concentration, a 10-μg/day increase in peak iAs daily dose rate, or an increase in cumulative iAs dose derived from 
50 years of drinking 1.5 L water/day containing 10 μg/L iAs. 
aMedian DMA%, 76.6%; median MA%, 15.8%. bThese ORs are stratum specific because they estimate effect of iAs 
on cancer as a linear effect, separately by level of metabolite, for both DMA% and MA%, and controlled for potential 
confounders county, age, sex, education, skin response to 1-hr midday sun, and skin complexion. cp-Values for multipli-
cative interaction terms between dichotomous variables for DMA% or MA% and   continuous variables for iAs exposure 
indexes (Wald test).Arsenic and cancer: Hungary, Romania, and Slovakia
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towns (1,238,984). The proportion of the 
base popu  lation in the larger cities and towns 
(35.4%) was comparable to the proportion of 
controls from the same areas (187 of 538 total 
controls, 34.8%), which suggests that the 
control group is representative of the base 
population. In addition, response rates were 
high and similar between cases and controls. 
However, iAs exposures were higher in the 
rural areas than in the urban subcounty areas, 
with average lifetime iAs concentrations of 
2.9 μg/L and 0.9 μg/L, respectively, and some 
residual bias cannot be ruled out completely.
Analysis of total concentrations of iAs in 
drinking water in the present study was based 
on established analytical chemistry techniques, 
and the QA/QC program demonstrated that 
measured concentrations of iAs were within 
acceptable margins of error. Thus, analytical 
data were suitable for estimating current expo-
sure from drinking water for all participants. 
Historic data provided by the water authori-
ties were based on older (and potentially less 
precise) methods, combined with estimated 
dates when water treatments were introduced. 
However, these data were provided by experts 
blind to whether the named communities 
hosted cases or controls.
Information on residences over the lifetime 
of participants, which was used to identify 
residences where water sources were available 
for sampling or to link past residences with 
historical iAs measurement data, was complete 
for most of the participants’ life-years (80%). 
The reconstruction of historic exposure to iAs 
in drinking water can therefore be considered 
adequate for production of exposure assess-
ment estimates and provides a more complete 
characterization of overall exposure than from 
current sources alone (Hough et al. 2010).
Most of the ASHRAM study population 
was using drinking water with low iAs con-
centrations (75% < 14 μg/L), well below con-
centrations in studies upon which the current 
drinking water standard is based. The use of 
individual measurements of iAs in drinking 
water for exposure estimation was validated 
by comparing the concentrations of iAs in the 
currently used water with the concentrations 
of iAs metabolites in urine, which is consid-
ered a good indicator of ongoing exposure 
(Lindberg et al. 2006). The concentrations of 
iAs in urine were significantly correlated with 
those in water (R2 = 0.46; p < 0.001).
Several potential confounders were mea-
sured and included in the analyses and had 
minimal effect. However, incomplete adjust-
ment for confounders remains a possibility.
We estimated the iAs effect when the 
analyses were restricted to the subgroup with 
sum of iAs metabolites ≥ 2.5 μg/L, based on 
the assumption that the relative contribution 
of food iAs intake to overall exposure is 
relatively low in this group. We found that 
associations between BCC and iAs exposure 
via water were very similar between this 
subgroup and the overall study population.
The possibility that exposure to low 
concentrations of iAs may be associated with 
BCC has been debated (Brown and Ross 
2002; Schoen et al. 2004). To exclude the 
possibility that the association between BCC 
and iAs was mainly due to the few cases using 
water with relatively high iAs concentration, 
we repeated the analyses after excluding cases 
and controls with an average iAs concentration 
at or above the 90th percentile of 40.7 μg/L. 
Associations within this subgroup were similar 
to, or somewhat stronger than, those for the 
overall study population, which suggests that 
if there is a threshold for iAs effects, it may be 
below an iAs lifetime average concentration 
of 40.7 μg/L. There is increasing evidence 
based on mechanistic research that very low 
concentrations of iAs induce cell proliferation, 
telomerase expression, increased telomere 
length, and oncogene overexpression, whereas 
higher concentrations induce apoptosis, 
telomerase inhibition, and decreased telomere 
length (Ferrario et al. 2009; Hwang et al. 
2006; Mo et al. 2009; Vega et al. 2001). There 
is additional mechanistic support for effects 
of iAs at very low dose levels, for example, via 
epigenetic and endocrine interactions (Arita 
and Costa 2009; Davey et al. 2007; Singh 
and DuMond 2007), as well as inhibition of 
DNA repair (Nollen et al. 2009). DNA repair 
genes may influence individual susceptibility 
to BCC (Thirumaran et al. 2006), and their 
role in iAs-related cancer also needs further 
investigation. In view of these possibilities, the 
overall pattern of iAs carcinogenic effects at 
low concentrations and possible mechanisms 
for low-dose effects need further study.
The pattern of risk in subgroups defined 
on the basis of iAs metabolism (DMA% and 
MA%) is broadly consistent with those of 
recent studies (Chen et al. 2003; Hsueh et al. 
1997; Yu et al. 2000) and suggests increasing 
risk of iAs-related skin cancer with increasing 
percentage of MA in urine. Most of the popu-
lations previously studied experienced rela-
tively high exposures, at which iAs methylation 
is inhibited, resulting in an increased percent-
age of urinary MA (Lindberg et al. 2007; 
Vahter 2002). Our findings suggest that the 
influence of metabolism is still present at fairly 
low iAs exposure levels, where iAs metabolism 
is mainly influenced by genetic predisposition 
(Lindberg et al. 2007). Possibly, MA in urine 
reflects the tissue levels of MA(III), a highly 
toxic intermediate metabolite (Drobná et al. 
2005; Kligerman et al. 2003).
Conclusions
We found positive associations between long-
term exposure to iAs < 100 μg/L in drinking 
water and BCC of the skin. The exposure metric 
that showed the most significant relation  ship 
with BCC was lifetime average water iAs con-
centration. The association between iAs and 
BCC remained significant in the subgroup 
exposed to iAs lifetime average water iAs con-
centration < 40 μg/L (90th percentile). Arsenic 
metabolism modified the risk of BCC such that 
the association with iAs appeared to be limited 
to participants with reduced iAs methyla  tion 
efficiency, reflected in low DMA% and high 
MA% in urine. Overall, our findings add to the 
evidence that low-dose exposure to iAs causes 
cancer and support current recommendations 
to minimize human exposure even at relatively 
low concentrations.
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